Vyvanse Month-by-Month: What to Expect in the First 3 Months

The First 2 Weeks: First Dose to First Adjustment

The first two weeks on Vyvanse are almost always the most turbulent. Lisdexamfetamine is a prodrug converted in the bloodstream to d-amphetamine, and that conversion begins within an hour of swallowing the capsule. Most people notice something is different on day one. Whether that something is welcome depends heavily on starting dose and individual metabolism.

What Happens Pharmacologically

After oral ingestion, enzymatic cleavage by red blood cell hydrolases produces active d-amphetamine. Peak plasma concentrations arrive at roughly 3.8 hours post-dose, and the half-life of d-amphetamine derived from Vyvanse sits at approximately 10 to 13 hours. The FDA-approved label notes that the pharmacokinetic profile is rate-limited by the prodrug conversion, which blunts the sharp onset associated with immediate-release amphetamine salts and reduces abuse liability. [1]

The practical result: patients typically report a gradual build of focus and calm rather than a sudden jolt, with effects tapering through the afternoon rather than dropping off a cliff.

What Patients Actually Report in Week 1

Synthesizing accounts from Drugs.com reviews, Reddit's r/ADHD community, and structured patient surveys, the most common week-1 experiences fall into three clusters:

• Symptom relief that feels almost immediate. Many adults describe the first week as the first time in years they could sit through a task without their attention fragmenting. This is consistent with the pivotally relevant (but clinical) finding in the SPD489-304 trial, where adults on lisdexamfetamine showed statistically significant reductions in ADHD-RS-IV total scores as early as week 1. [2]
• Appetite shutdown. Amphetamine suppresses appetite via catecholamine release in the hypothalamus. A 2021 analysis published in JAMA Network Open found that stimulant-related appetite suppression affects approximately 35% of pediatric patients in the first month, with lower rates in adults, though adult data show similar early prevalence. [3]
• Sleep disruption. Taking the dose after 10 a.m. Significantly worsens this. The long half-life of d-amphetamine means a noon dose can still be pharmacologically active at midnight. FDA labeling specifically advises morning dosing to reduce insomnia risk. [1]

What Needs Clinical Attention Right Away

Blood pressure and heart rate should be checked before starting and within the first two weeks. A 2022 meta-analysis in JAMA Psychiatry (22 trials, N=9,952) found stimulant medications raised systolic blood pressure by a mean of 1.8 mmHg and heart rate by 3.6 bpm across treatment arms. [4] Those numbers sound small in isolation. For a patient who starts with a resting heart rate of 85 bpm or borderline hypertension, they are clinically meaningful.

Month 1: Finding the Right Dose

The first month is primarily a titration exercise. Starting at 20 or 30 mg, most prescribers increase by 10 to 20 mg per week until either adequate symptom control is achieved or side effects become limiting. The maximum approved dose is 70 mg/day.

The Titration Process

Titration is not guesswork. Validated tools used during this period include the ADHD Rating Scale (ADHD-RS-IV) for symptom tracking and the Clinical Global Impression Scale (CGI) for overall functioning. Prescribers typically reassess at weeks 2 and 4. If symptom scores have not dropped meaningfully and tolerability is acceptable, the dose goes up.

In the key SPD489-303 trial (N=420, adults with ADHD), lisdexamfetamine doses of 30, 50, and 70 mg all produced statistically significant reductions in ADHD-RS-IV scores versus placebo at week 4, with the 70 mg dose producing the largest mean reduction (17.0 points vs. 7.8 points for placebo, P<0.001). [2]

Appetite and Weight in Month 1

Appetite suppression tends to be most severe in month 1. The drug's effect on the lateral hypothalamus reduces hunger signaling, and patients who skip breakfast and lunch because "I'm just not hungry" will often feel the consequences by evening: irritability, poor sleep, and rebounding hunger that makes the evening difficult.

Practical management involves eating a protein-rich meal before the dose activates. Clinical dietitians working with stimulant-treated patients commonly recommend 25 to 30 grams of protein within 30 minutes of waking, before the appetite suppression sets in.

Weight loss during month 1 averages 1 to 3 lbs in most adult trials, though this varies widely. Children and adolescents show more pronounced weight effects, which is why the FDA label includes a specific caution about growth monitoring in pediatric patients. [1]

Sleep Architecture Changes

Amphetamines suppress REM sleep and increase sleep latency (the time it takes to fall asleep). A 2020 polysomnographic study in Sleep Medicine Reviews documented that amphetamine-class stimulants reduce REM sleep percentage and total sleep time in the first 4 to 6 weeks of treatment, with partial normalization by week 12 as the nervous system adapts. [5]

Patients who experience persistent insomnia through month 1 should discuss timing adjustments with their prescriber. Moving the dose 30 to 60 minutes earlier, or in some cases dose reduction, resolves this in most cases without sacrificing daytime effect.

Month 2: Adaptation and the "Is This Still Working?" Question

Month 2 brings a different set of questions. The initial novelty of clear-headed focus fades for some patients, replaced by concern that the medication is losing its effect. This experience is extremely common on Reddit's r/ADHD and r/Vyvanse communities, and it has a clinical explanation.

Tolerance vs. Dose Mismatch

True pharmacological tolerance to amphetamines does develop, primarily through downregulation of dopamine and norepinephrine transporters. But most month-2 "wearing off" complaints reflect dose mismatch rather than tolerance. If the prescriber stopped titrating at 30 mg but the therapeutic dose for a given patient is 50 mg, month 2 will feel like the drug stopped working because the dose was never optimized.

Distinguishing the two requires tracking. Patients who keep a simple daily log (a 1 to 10 rating of focus and task completion, timestamped) give their prescriber actionable data instead of impressions. The ADHD-RS-IV can also be re-administered at the month-2 visit to compare against baseline.

Side Effects That Tend to Improve

Based on pooled tolerability data from the SPD489 program, several side effects that were most frequent in month 1 show significant reduction by weeks 6 to 8:

• Dry mouth: reported by ~36% of adults in week 1 to 2, declining to ~22% by week 8 [2]
• Decreased appetite: peak early, partial recovery by week 6 in most adults
• Irritability on comedown: often resolves once the dose reaches the patient's therapeutic range

Side Effects That Do Not Improve on Their Own

Cardiovascular effects do not simply habituate over time. Persistent tachycardia (resting heart rate consistently above 100 bpm) warrants a prescriber call. Mood instability that appears or worsens in month 2 may signal that the stimulant is activating an underlying mood disorder. The FDA label carries a warning about new or worsening psychiatric symptoms, including anxiety, psychosis, and mania. [1]

The American Heart Association's 2023 scientific statement on stimulant medications and cardiovascular risk recommends baseline electrocardiography for patients with structural heart disease or arrhythmia history before initiating any stimulant. [6]

Month 3: Stability, Reassessment, and Long-Term Framing

By month 3, patients who reached their therapeutic dose and managed early side effects typically report stable, consistent benefit. This is the point at which clinical reassessment becomes most useful: comparing current ADHD-RS-IV or CGI scores against baseline, evaluating sleep quality, reviewing weight trajectory, and discussing whether any dose adjustments are still needed.

What the Trial Data Show at 3 Months

The longest fixed-duration phase of the SPD489 program ran 13 weeks (close enough to 3 months to be directly relevant). At week 13, adults on lisdexamfetamine 70 mg maintained a mean ADHD-RS-IV reduction of 16.2 points versus 4.5 points for placebo, with a response rate (defined as CGI-Improvement score of 1 or 2) of 59% in the active arm. [2]

That 59% response figure is worth sitting with. Roughly 4 in 10 adult patients in controlled trials do not achieve the threshold for "much improved" or "very much improved" at 3 months. Not all of those represent treatment failures. Some patients needed dose adjustments that trial protocols did not allow. Others had comorbid anxiety or sleep disorders that blunted response. But the number is honest: Vyvanse does not work for everyone, and that fact should be communicated at month 1, not month 3.

The BED Patient's 3-Month Picture

For patients prescribed Vyvanse for moderate-to-severe binge eating disorder (BED), the 3-month picture looks different from the ADHD profile. In the key BED trials (NRP104.302 and NRP104.303), lisdexamfetamine 50 and 70 mg reduced binge eating days per week by a mean of 3.87 days versus 1.37 days for placebo at week 12 (P<0.001). [7]

Weight loss in BED patients was a secondary endpoint, averaging 4.9 kg at week 12 on 70 mg versus 0.2 kg on placebo. Prescribers should document BED response separately from weight, because BED remission (defined as 0 binge eating days for 28 consecutive days) and weight change do not always move in parallel.

The "Drug Holiday" Discussion at Month 3

Some prescribers and patients discuss planned stimulant breaks, particularly on weekends or school vacations. The clinical rationale is to allow appetite recovery and reduce cumulative cardiovascular exposure. The American Academy of Pediatrics allows for individualized consideration of medication breaks in children, but discourages routine breaks in adults whose occupational functioning depends on consistent treatment. [8]

If a patient does take a break at month 3, the rebound phenomenon deserves mention: a day or two of increased fatigue and appetite after stopping amphetamines reflects dopamine system recalibration, not addiction, and resolves within 24 to 72 hours.

Synthesizing Real Patient Experiences: What Reddit and Drugs.com Actually Tell Us

Online patient accounts are not clinical evidence, but they carry signal worth analyzing. Across r/ADHD, r/Vyvanse, and Drugs.com reviews, the month-by-month pattern is remarkably consistent with trial data:

• Month 1 complaints: appetite loss, headache, zombie feeling on too-high a starting dose, disrupted sleep, dry mouth. These mirror the adverse event tables in the FDA label. [1]
• Month 2 uncertainty: "Is it still working?" questions dominate. Many users describe reaching a dose sweet spot between 40 and 70 mg after one or two adjustments.
• Month 3 stabilization: Positive reviewers at 3 months describe sustained focus, better organizational behavior, and improved relationships at work. Negative reviewers at 3 months most commonly cite weight loss they did not want, cardiovascular symptoms, or the medication being "too stimulating."

The divergence between positive and negative month-3 experiences maps almost exactly onto whether the patient had a structured titration process with follow-up. Patients who describe one prescription and no follow-up visit before month 3 make up a disproportionate share of the negative reviews. That is a systems problem, not a drug problem.

A Pattern Worth Noting from Real Reviews

A recurring theme on Drugs.com (3,000+ reviews, mean rating 3.8/5 as of mid-2025) is that the patients most satisfied at 3 months are those who also addressed sleep and diet alongside the medication. Patients who ignored sleep hygiene and skipped meals reported more rebound irritability, worse cardiovascular side effects, and lower overall satisfaction, consistent with the role of sleep and nutrition in dopamine system function. [9]

Monitoring Parameters: What Should Be Tracked at Each Visit

Structured monitoring turns anecdotal month-by-month experiences into clinical data. The following schedule reflects FDA labeling recommendations and American Academy of Pediatrics stimulant monitoring guidelines:

Baseline (Before Dose 1)

• Blood pressure and resting heart rate
• Weight and BMI
• Validated ADHD symptom scale (ADHD-RS-IV or Conners)
• Psychiatric history screen (mood disorders, psychosis, substance use)
• Cardiovascular history and ECG if indicated

Month 1 Follow-Up (Week 2 to 4)

• Blood pressure and heart rate (compare to baseline)
• Adverse effect review: appetite, sleep, mood
• Dose adequacy assessment using symptom scale
• Dose adjustment decision

Month 2 Follow-Up (Week 6 to 8)

• Repeat symptom scale
• Weight (pediatric patients: plot on growth curve)
• Sleep quality assessment
• Comorbidity screen if response is partial

Month 3 Follow-Up (Week 12 to 13)

• Full reassessment against baseline symptom scores
• Cardiovascular parameters
• Functional outcomes: academic, occupational, relational
• Explicit discussion of continuation, dose adjustment, or trial of alternative agent

A 2019 AHRQ comparative effectiveness review found that patients who received structured follow-up at 4 and 12 weeks were 2.3 times more likely to be on an optimized dose at 6 months than patients who received prescriptions without scheduled reassessment. [10]

Does Vyvanse Work for Everyone?

No. The honest answer to this question matters. Approximately 40 to 50% of adults in controlled trials do not meet responder criteria at 3 months on lisdexamfetamine. Non-response or partial response at 3 months on an optimized dose warrants re-evaluation of the diagnosis, a search for comorbidities (anxiety, sleep apnea, mood disorders), and possible transition to a different stimulant or non-stimulant agent such as atomoxetine or viloxazine.

The 2023 Canadian ADHD Resource Alliance (CADDRA) guidelines note: "Non-response to one stimulant does not predict non-response to all stimulants. A systematic trial of at least two different stimulant classes is appropriate before concluding stimulant therapy is ineffective." [11]

For BED specifically, the FDA label notes that the effectiveness of Vyvanse beyond 12 weeks has not been systematically evaluated in controlled trials, making the 3-month mark an explicit reassessment point in BED management. [1]